Welcome to our dedicated page for Sagimet Biosciences SEC filings (Ticker: SGMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with drug-trial data and cash-runway tables can drain hours. Sagimet Biosciences鈥� 10-K alone layers complex R&D footnotes over dense risk factors tied to its FASN program. If you are searching 鈥淪agimet Biosciences SEC filings explained simply鈥� or wondering how Form 4 insider trades may signal management鈥檚 confidence, you have likely met this challenge.
Stock Titan solves it. Our AI reads every Sagimet Biosciences annual report 10-K, quarterly earnings report 10-Q filing, and 8-K material event the moment EDGAR posts them. It then delivers concise, plain-English summaries that highlight R&D spend, denifanstat trial milestones, and liquidity updates鈥攅xactly what analysts look for. AG真人官方-time alerts flag 鈥淪agimet Biosciences insider trading Form 4 transactions鈥� so you can track executive stock moves without sifting through PDFs. Need quick answers? Ask, 鈥淲here is Sagimet Biosciences鈥� proxy statement executive compensation?鈥� and our platform directs you to the page and provides context.
Investors use these insights to:
- Compare quarter-over-quarter clinical expenses across business segments
- Monitor 鈥淪agimet Biosciences Form 4 insider transactions real-time鈥� for buying or selling patterns
- Decode 8-K disclosures on trial results or financing agreements within minutes
Whether you are analysing a fresh 10-Q or revisiting a past 10-K, Stock Titan delivers comprehensive coverage, AI-powered summaries, and expert analysis so you can understand Sagimet Biosciences filings quickly and act with confidence.
Thermo Fisher Scientific (TMO) filed an 8-K announcing a planned CFO transition.
Senior Vice President & Chief Financial Officer Stephen Williamson will retire effective March 31 2026. To provide continuity, the board has appointed James R. Meyer (age 46), currently Vice President, Financial Operations, to become Senior Vice President & CFO effective March 1 2026. Meyer joined the company in 2009 and has held progressively senior finance roles, including VP of Finance, Customer Channels (2020-2022), before assuming his present post in January 2023; he previously worked at PwC.
No financial results, guidance, debt transactions or other material events were disclosed. The orderly, internally sourced succession suggests minimal operational disruption, although leadership change can introduce short-term uncertainty. Compensation or severance terms were not included in this filing.
Q2 2025 snapshot: Baker Hughes (BKR) reported revenue of $6.91 bn, down 3.2% YoY as lower Oilfield Services & Equipment (OFSE) activity offset 5% growth in Industrial & Energy Technology (IET). Aggressive cost control lifted profitability: net income climbed 21% to $701 m and diluted EPS rose 22% to $0.71. Segment EBITDA margin expanded 80 bp to 18.3%.
Cash & balance sheet: Operating cash flow improved 7.7% to $1.22 bn and, after $0.60 bn capex, produced roughly $0.62 bn free cash flow. Cash ended at $3.09 bn versus $6.03 bn gross debt; the $3 bn revolver remains undrawn. Shareholder returns totalled $652 m in Q2 and $840 m year-to-date via dividends ($456 m) and buybacks ($384 m, 9.8 m shares).
Strategic moves: A $540 m agreement to acquire Continental Disc will deepen pressure-management offerings (close expected Q3). Two businesses were classified as held-for-sale: Precision Sensors & Instrumentation ($1.15 bn cash sale) and Surface Pressure Control (JV, $345 m cash plus 35% stake). Remaining performance-obligation backlog stands at $34 bn, providing multi-year visibility.
Outlook & policy: Management anticipates subdued 2025 upstream spending but solid LNG demand. The newly enacted OBBBA keeps the U.S. statutory tax rate at 21% and eases interest-expense limits; full earnings impact is under review.
Q2 2025 snapshot: Baker Hughes (BKR) reported revenue of $6.91 bn, down 3.2% YoY as lower Oilfield Services & Equipment (OFSE) activity offset 5% growth in Industrial & Energy Technology (IET). Aggressive cost control lifted profitability: net income climbed 21% to $701 m and diluted EPS rose 22% to $0.71. Segment EBITDA margin expanded 80 bp to 18.3%.
Cash & balance sheet: Operating cash flow improved 7.7% to $1.22 bn and, after $0.60 bn capex, produced roughly $0.62 bn free cash flow. Cash ended at $3.09 bn versus $6.03 bn gross debt; the $3 bn revolver remains undrawn. Shareholder returns totalled $652 m in Q2 and $840 m year-to-date via dividends ($456 m) and buybacks ($384 m, 9.8 m shares).
Strategic moves: A $540 m agreement to acquire Continental Disc will deepen pressure-management offerings (close expected Q3). Two businesses were classified as held-for-sale: Precision Sensors & Instrumentation ($1.15 bn cash sale) and Surface Pressure Control (JV, $345 m cash plus 35% stake). Remaining performance-obligation backlog stands at $34 bn, providing multi-year visibility.
Outlook & policy: Management anticipates subdued 2025 upstream spending but solid LNG demand. The newly enacted OBBBA keeps the U.S. statutory tax rate at 21% and eases interest-expense limits; full earnings impact is under review.
Sagimet Biosciences (SGMT) received an Amendment No. 1 to Schedule 13G from AP11 Limited and Ascletis Pharma Inc., dated 24 June 2025 and filed 29 June 2025. The filing reports beneficial ownership of 1,504,642 Series A common shares, equal to 4.9 % of the 30,674,855 shares outstanding as cited in Sagimet鈥檚 10 June 2025 Form 8-K.
The reporting persons each claim sole voting and dispositive power over the entire position and report no shared power and no group status. Item 5 confirms 鈥渙wnership of 5 percent or less,鈥� meaning the investors are no longer 5 % holders under SEC rules. No additional transactions, control arrangements, or contingent rights are disclosed, and the document contains no risk factors, legal matters, or financial projections.
Overall, the amendment simply updates Sagimet鈥檚 ownership ledger, signalling that two related offshore entities now hold a sub-5 % passive stake without seeking influence over the issuer鈥檚 governance.
FAQ
What is the current stock price of Sagimet Biosciences (SGMT)?
What is the market cap of Sagimet Biosciences (SGMT)?
What is the core focus of Sagimet Biosciences Inc.?
What is denifanstat and why is it significant?
How does Sagimet generate value through its technology?
What clinical programs are currently emphasized by the company?
How does Sagimet differentiate itself from other biopharmaceutical companies?
Are there additional therapeutic areas beyond liver diseases in Sagimet's pipeline?
What role do clinical trials play in Sagimet鈥檚 development strategy?
How does the company ensure scientific rigor and reliability?
What is the overall market significance of Sagimet Biosciences Inc.?
